An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis

Science. 2020 Feb 7;367(6478):652-660. doi: 10.1126/science.aay0542.

Abstract

Liver cell death has an essential role in nonalcoholic steatohepatitis (NASH). The activity of the energy sensor adenosine monophosphate (AMP)-activated protein kinase (AMPK) is repressed in NASH. Liver-specific AMPK knockout aggravated liver damage in mouse NASH models. AMPK phosphorylated proapoptotic caspase-6 protein to inhibit its activation, keeping hepatocyte apoptosis in check. Suppression of AMPK activity relieved this inhibition, rendering caspase-6 activated in human and mouse NASH. AMPK activation or caspase-6 inhibition, even after the onset of NASH, improved liver damage and fibrosis. Once phosphorylation was decreased, caspase-6 was activated by caspase-3 or -7. Active caspase-6 cleaved Bid to induce cytochrome c release, generating a feedforward loop that leads to hepatocyte death. Thus, the AMPK-caspase-6 axis regulates liver damage in NASH, implicating AMPK and caspase-6 as therapeutic targets.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / genetics
  • AMP-Activated Protein Kinases / metabolism*
  • Animals
  • Apoptosis / genetics
  • Caspase 3 / metabolism
  • Caspase 6 / metabolism*
  • Caspase 7 / metabolism
  • Caspase Inhibitors / pharmacology
  • Caspase Inhibitors / therapeutic use
  • Enzyme Activation
  • Hepatocytes / enzymology
  • Hepatocytes / pathology
  • Humans
  • Liver / enzymology*
  • Liver / pathology*
  • Mice
  • Mice, Knockout
  • Non-alcoholic Fatty Liver Disease / drug therapy
  • Non-alcoholic Fatty Liver Disease / enzymology*
  • Non-alcoholic Fatty Liver Disease / pathology*
  • Phosphorylation

Substances

  • Caspase Inhibitors
  • AMP-Activated Protein Kinases
  • Caspase 3
  • Caspase 6
  • Caspase 7